Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
Bionoid Pharma (OTC PINK:BINP) has appointed Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year 2024. This strategic move follows the company's recent application to uplist to the OTCQB Venture Market.
The engagement of the new auditor demonstrates Bionoid's focus on enhancing financial governance and transparency, aimed at providing investors with improved visibility and liquidity. The audit is positioned as a important step in the company's strategy to achieve a more senior market listing.
Bionoid Pharma (OTC PINK:BINP) ha nominato Aloba, Awomolo & Partners, una società di contabilità registrata presso il PCAOB, come suo revisore contabile esterno indipendente per l'anno fiscale 2024. Questa mossa strategica segue la recente richiesta dell'azienda di passare al Mercato OTCQB Venture.
Il coinvolgimento del nuovo revisore dimostra l'impegno di Bionoid a migliorare la governance finanziaria e la trasparenza, con l'obiettivo di fornire agli investitori una maggiore visibilità e liquidità. L'audit è considerato un passo importante nella strategia dell'azienda per ottenere una quotazione di mercato più elevata.
Bionoid Pharma (OTC PINK:BINP) ha nombrado a Aloba, Awomolo & Partners, una firma de contabilidad registrada en PCAOB, como su auditor externo independiente para el año fiscal 2024. Este movimiento estratégico sigue a la reciente solicitud de la empresa para ascender al Mercado OTCQB Venture.
La contratación del nuevo auditor demuestra el enfoque de Bionoid en mejorar la gobernanza financiera y la transparencia, con el objetivo de proporcionar a los inversores una mayor visibilidad y liquidez. La auditoría se posiciona como un paso importante en la estrategia de la empresa para lograr una cotización en un mercado más avanzado.
Bionoid Pharma (OTC PINK:BINP)는 Aloba, Awomolo & Partners를 2024 회계 연도의 독립 외부 감사인으로 임명했습니다. 이 전략적 결정은 회사가 OTCQB 벤처 시장으로 상장 신청을 한 후 이루어졌습니다.
새로운 감사인의 참여는 Bionoid가 재무 거버넌스 및 투명성을 향상시키려는 의지를 보여주며, 투자자들에게 향상된 가시성과 유동성을 제공하는 것을 목표로 하고 있습니다. 이번 감사는 회사의 더 높은 시장 상장을 위한 전략의 중요한 단계로 자리잡고 있습니다.
Bionoid Pharma (OTC PINK:BINP) a nommé Aloba, Awomolo & Partners, un cabinet comptable enregistré auprès du PCAOB, en tant qu'auditeur externe indépendant pour l'exercice fiscal 2024. Ce mouvement stratégique fait suite à la récente demande de l'entreprise de passer au Marché OTCQB Venture.
L'engagement du nouvel auditeur démontre l'engagement de Bionoid à améliorer la gouvernance financière et la transparence, visant à offrir aux investisseurs une meilleure visibilité et liquidité. L'audit est positionné comme une étape importante dans la stratégie de l'entreprise pour obtenir une cotation sur un marché plus senior.
Bionoid Pharma (OTC PINK:BINP) hat Aloba, Awomolo & Partners, eine beim PCAOB registrierte Wirtschaftsprüfungsgesellschaft, als unabhängigen externen Prüfer für das Geschäftsjahr 2024 ernannt. Dieser strategische Schritt folgt auf den kürzlichen Antrag des Unternehmens, an die OTCQB Venture Market aufzusteigen.
Die Beauftragung des neuen Prüfers zeigt Bionoids Fokus auf die Verbesserung der finanziellen Governance und Transparenz, mit dem Ziel, den Investoren eine bessere Sichtbarkeit und Liquidität zu bieten. Die Prüfung wird als wichtiger Schritt in der Strategie des Unternehmens angesehen, um eine höherwertige Marktlistung zu erreichen.
- Applied for uplisting to OTCQB Venture Market, potentially increasing stock visibility and liquidity
- Engagement of PCAOB-registered auditor strengthens financial governance
- Currently trading on OTC Pink, the lowest tier of OTC Markets
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024.
This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value.
"We are pleased to welcome Aloba, Awomolo & Partners as our auditors for the 2024 fiscal year," said a spokesperson for Bionoid Pharma Inc. "Their expertise will be instrumental as we advance our financial reporting standards. Following our recent application to uplist to the OTCQB Venture Market, this audit represents a critical step toward achieving a more senior listing and reflects our dedication to providing investors with increased visibility and liquidity."
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: https://bionoidpharma.com
https://aimaverickintel.com/
OTC Markets: BINP
X (formerly Twitter): @BionoidPharminc
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the significance of BINP engaging Aloba, Awomolo & Partners as auditor?
When will Aloba, Awomolo & Partners audit BINP's financial statements?
What are the potential benefits for BINP shareholders from the OTCQB uplisting plan?
What market does BINP currently trade on?
